Problem to be solved: To provide a novel skin-whitening agent that inhibits the production of melanin in melanocytes induced by endothelin and α-MSH, and further inhibits the deposition of melanin produced in melanocytes on keratinocytes.
Solution: The features of the invention designed to solve the above problem are as follows:
(1) An inhibitor of melanin production in melanocytes induced by endothelin and α-MSH, which contains maqui berry extract as an active component.
(2) An inhibitor of melanin deposition on keratinocytes containing maqui berry extract as an active component.
(3) A skin-whitening agent containing maqui berry extract as an active component.
Prophylactic/Therapeutic Agent for Dry Eye
Product name
Maqui Berry Extract
Title of invention
Prophylactic/therapeutic agent for dry eye
Patent number
6265500
Date of filing
December 17, 2013
Date of grant
January 5, 2018
Summary
Provided is a prophylactic/therapeutic agent for dry eye containing a novel component, which suppresses deterioration in tear secretion capacity and inhibits the production of active oxygen in the lacrimal gland tissue. The prophylactic/therapeutic agent for dry eye contains maqui berry extract as an active component. In addition, the prophylactic/therapeutic agent for dry eye contains delphinidin glycoside extracted from maqui berry as an active component. Further, the prophylactic/therapeutic agent for dry eye contains at least one of Delphinidin-3-sambubioside-5-glucoside, Delphinidin-3,5-diglucoside, Delphinidin-3-sambubioside, and Delphinidin-3-glucoside, preferably Delphinidin-3,5-diglucoside, as an active component.
Prophylactic/Therapeutic Agent for Dry Eye
Product name
Maqui Berry Extract
Title of invention
Prophylactic/therapeutic agent for dry eye
Patent number
CA2895353
Date of filing
December 17, 2013
Date of grant
October 1, 2019
Summary
Provided is a prophylactic/therapeutic agent for dry eye, which comprises a novel component capable of preventing the deterioration of a tear fluid secretion ability and also capable of inhibiting the generation of active oxygen in tear gland tissues. The prophylactic/therapeutic agent for dry eye according to the present invention contains a maqui berry extract as an active ingredient. The prophylactic/therapeutic agent for dry eye according to the present invention may contain, as an active ingredient, a delphinidin glycoside that is extracted from maqui berry. The prophylactic/therapeutic agent for dry eye according to the present invention may contain at least one component selected from delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, desirably delphinidin-3,6-diglucoside, as an active ingredient.
Prophylactic/Therapeutic Agent for Dry Eye
Product name
Maqui Berry Extract
Title of invention
Prophylactic/therapeutic agent for dry eye
Patent number
10-2070479
Date of filing
December 17, 2013
Date of grant
January 20, 2020
Summary
Provided is a prophylactic/therapeutic agent for dry eye containing a novel component, which suppresses deterioration in tear secretion capacity and inhibits the production of active oxygen in the lacrimal gland tissue. The prophylactic/therapeutic agent for dry eye contains maqui berry extract as an active component. In addition, the prophylactic/therapeutic agent for dry eye contains delphinidin glycoside extracted from maqui berry as an active component. Further, the prophylactic/therapeutic agent for dry eye contains at least one of Delphinidin-3-sambubioside-5-glucoside, Delphinidin-3,5-diglucoside, Delphinidin-3-sambubioside, and Delphinidin-3-glucoside, preferably Delphinidin-3,5-diglucoside, as an active component.
Prophylactic/Therapeutic Agent for Dry Eye
Product name
Maqui Berry Extract
Title of invention
Prophylactic/therapeutic agent for dry eye
Patent number
US11033566
Date of filing
December 17, 2013
Date of grant
June 15, 2021
Summary
Provided is a prophylactic/therapeutic agent for dry eye, which comprises a novel component capable of preventing the deterioration of a tear fluid secretion ability and also capable of inhibiting the generation of active oxygen in tear gland tissues. The prophylactic/therapeutic agent for dry eye according to the present invention contains a maqui berry extract as an active ingredient. The prophylactic/therapeutic agent for dry eye according to the present invention may contain, as an active ingredient, a delphinidin glycoside that is extracted from maqui berry. The prophylactic/therapeutic agent for dry eye according to the present invention may contain at least one component selected from delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, desirably delphinidin-3,5-diglucoside, as an active ingredient.
Prophylactic/Therapeutic Agent for Dry Eye
Product name
Maqui Berry Extract
Title of invention
Prophylactic/therapeutic agent for dry eye
Patent number
239478
Date of filing
December 17, 2013
Date of grant
February 1, 2019
Summary
Provided is a prophylactic/therapeutic agent for dry eye, which comprises a novel component capable of preventing the deterioration of a tear fluid secretion ability and also capable of inhibiting the generation of active oxygen in tear gland tissues. The prophylactic/therapeutic agent for dry eye according to the present invention contains a maqui berry extract as an active ingredient. The prophylactic/therapeutic agent for dry eye according to the present invention may contain, as an active ingredient, a delphinidin glycoside that is extracted from maqui berry. The prophylactic/therapeutic agent for dry eye according to the present invention may contain at least one component selected from delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, desirably delphinidin-3,5-diglucoside, as an active ingredient.
Patents
